Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Latest analysis of No…
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis atrasentan Phase III data show clinica…
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis Phase III data confirm sustained efficacy and long-term s…
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
arcticnovartis
Mon, 05/05/2025 – 13:04…
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
arcticnovartis
Mon, 05/05/2025 – 13:04…
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
…
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis highlights pioneering innovation in CML…
Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipel…
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis and Medicines for Malaria Venture announce…
Novartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal
arcticnovartis
Tue, 04/29/2025 – 07:03
Read more about Novartis setzt die starke Dynamik fort mit zweis…
